<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04769752</url>
  </required_header>
  <id_info>
    <org_study_id>Guinot 2021</org_study_id>
    <nct_id>NCT04769752</nct_id>
  </id_info>
  <brief_title>Beta Blocker Use in Cardiac Surgery and Association With Postoperative Course</brief_title>
  <acronym>BLOCK</acronym>
  <official_title>Use and Prescription of Beta-blockers Before Cardiac Surgery With Cardiopulmopnary Bypass: Multicenter Observational Analysis of Practices and Its Association With Postoperative Morbidity-mortality.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to describe in a cohort of cardiac surgery patients the use of&#xD;
      beta-blockers before surgery and their maintenance or withdraw according to international&#xD;
      recommendations in order to compare patients who receive a beta-blocker with maintenance&#xD;
      during the surgical period (international recommendation) to those for whom prescription and&#xD;
      maintenance are not respected. Patients are treated according to standard practice and this&#xD;
      protocol does not change patient management. No additional information or data is required by&#xD;
      the study other than the data usually collected in the patient record (drug treatment,&#xD;
      medical history, operating data, postoperative data, complications, length of stay).&#xD;
&#xD;
      The objectives of this research are :&#xD;
&#xD;
        -  To evaluate the proportion of patients receiving beta-blocker treatment prior to cardiac&#xD;
           surgery.&#xD;
&#xD;
        -  To evaluate the proportion of patients receiving beta-blocker treatment before cardiac&#xD;
           surgery and complying with international recommendations for its maintenance/stop in&#xD;
           perioperative cardiac surgery.&#xD;
&#xD;
        -  To evaluate the incidence of complications and length of hospital stay in patients&#xD;
           receiving beta-blockers based on compliance or non-compliance with recommendations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients treated with beta-blocker in accordance with international guidelines</measure>
    <time_frame>7 days</time_frame>
    <description>Number of patients treated with beta-blocker in accordance with international guidelines</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Cardiac Surgery With Cardiopulmonary Bypass</condition>
  <arm_group>
    <arm_group_label>No beta-blocker</arm_group_label>
    <description>Patient do no treat with beta-blocker before the surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Beta blocker</arm_group_label>
    <description>Patient treat with beta-blocker in accordance to international guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Beta blocker2</arm_group_label>
    <description>Patient treat with beta-blocker without respect of international guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>collection of the allocated treatment</intervention_name>
    <description>collection of the allocated treatment</description>
    <arm_group_label>Beta blocker</arm_group_label>
    <arm_group_label>No beta-blocker</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>collection of medical complications</intervention_name>
    <description>collection of medical complications</description>
    <arm_group_label>Beta blocker</arm_group_label>
    <arm_group_label>No beta-blocker</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive cardiac surgical patients who meeet inclusion criteria with cardiopulmonary&#xD;
        bypass&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major patient ≥ 18 years&#xD;
&#xD;
          -  Patient operated cardiac surgery with cardiopulmonary bypass&#xD;
&#xD;
          -  Patients who have given oral consent to participate after full information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Off pump cardiac surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Chu Dijon Bourogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-grégoire GUINOT</last_name>
      <email>guinotpierregregoire@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

